Cited by 75Gut microbiota and healthNeuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatments

Gut microbiota-driven neuroinflammation in Alzheimer's disease: from mechanisms to therapeutic opportunities

Open access
Lei, Wenhui, Cheng, Yiwen, Liu, Xia, Gao, Jie, Zhu, Zhangcheng, Ding, Wenwen, Xu, Xiaocui, Li, Yating +3 more·2025·Frontiers in Immunology

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-beta (Aβ) plaques, tau hyperphosphorylation, and chronic neuroinflammation. While neuroinflammation—mediated by microglial and astrocyte activation—has long been considered a secondary response to Aβ pathology, emerging evidence positions it as a primary driver of cognitive decline. Notably, the gut microbiota, through the microbiota-gut-brain axis (MGBA), is crucial in modulating neuroinflammation. Dysbiosis disrupts gut barrier integrity, promotes systemic inflammation, and exacerbates neuroinflammatory responses, thereby accelerating AD progression. Recent advances reveal that gut microbiota-derived metabolites (e.g., short-chain fatty acids, lipopolysaccharides) directly influence microglial activation and Aβ aggregation. These findings have opened new therapeutic possibilities, with microbiota-targeted approaches such as probiotics, prebiotics, and fecal microbiota transplantation demonstrating promising neuroprotective effects in preclinical studies by reducing neuroinflammation and preserving cognitive function. However, translating these findings into clinical applications requires further validation through randomized controlled trials. This review summarizes the current understanding of gut microbiota-driven neuroinflammation in AD, from molecular mechanisms to potential therapeutic strategies. Targeting the MGBA represents a paradigm shift in AD management, emphasizing the modulation of neuroinflammation and pathological progression through gut microbiota interventions. The discussion also addresses existing research challenges and outlines future directions to advance this promising field.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2025.1582119

Cites

222 of 222 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Lei, W., Cheng, Y., Liu, X., Gao, J., Zhu, Z., Ding, W., Xu, X., Li, Y., Ling, Z., Jiang, R., & Chen, X.
Affiliations
  • First Affiliated Hospital Zhejiang University (CN)
  • Wenzhou Medical University (CN)
  • Nantong University (CN)
Corresponding author
  • Ling, Zongxin
  • Jiang, Ruilai
  • Chen, Xiaoying
Venue
Frontiers in Immunology
Published
2025-06-26
Volume
16
Pages
1582119-1582119
ISSN
1664-3224 (ISSN-L)
OpenAlex
W4411664782
Cited by
68
References
222
Citations by year
2026: 60 · 2025: 8
FWCI
6.02
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China
  • State Key Laboratory for Diagnosis and Treatment of Infectious Diseases
  • Fundamental Research Funds for the Central Universities (2022ZFJH003)
  • Natural Science Foundation of Zhejiang Province (LQ24H090005)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
Alzheimer's disease, gut microbiota, neuroinflammation, microbiota-gut-brain axis, dysbiosis, intestinal barrier integrity, short-chain fatty acids, lipopolysaccharide, microglial activation, amyloid-beta aggregation, tau hyperphosphorylation, probiotics, prebiotics, fecal microbiota transplantation, cognitive decline
MeSH terms
Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Brain-Gut Axis, Neuroinflammatory Diseases, Alzheimer Disease, Animals, Brain, Humans, Probiotics, Dysbiosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review